期刊文献+

溶瘤病毒H101结合局部加热治疗对转移肿瘤病灶的远端效应 被引量:12

Abscopal Effect on Metastatic Tumor Induced by Oncolytic Virus of H101 Combining with Local Heating
下载PDF
导出
摘要 背景与目的:远端效应是肿瘤的局部治疗引起的远处抗肿瘤作用。本研究探索溶瘤腺病毒H101局部注射结合局部加热治疗诱发远端抗瘤效应的可行性。方法:放化疗失败或拒绝放化疗并有转移病灶的5例肿瘤患者(2例鼻咽癌,1例肺癌,1例骨旁质肉瘤和1例膀胱癌),以H101(5×1011~15×1011VP)瘤内注射联合60min42℃局部热疗进行治疗。结果:2例患者注射灶、非注射灶肿瘤完全消退而长期生存,3例患者也观察到非注射病灶有不同程度缓解后死亡,生存期分别为29、15、13个月。结论:H101瘤内注射联合加热治疗能诱发一定的远端抗瘤效应。 BACKGROUND & OBJECTIVE: The abscopal effect on the tumors is a distant antitumor activity induced by local treatments. The study was to observe the induction of abscopal effect by the combination of H101 oncolytic virotherapy with local heating. METHODS: Five patients with histologically confirmed, surgically unresectable metastatic malignant tumors (2 nasopharyngeal carcinomas, 1 pulmonary carcinoma, 1 parosteal sarcoma and 1 bladder carcinoma) that had definitely failed to the conventional chemotherapy and radiotherapy or refused these therapies were enrolled in this experimental therapy, All patients were treated with local intra tumor injection of H101 (5×10^11~15×10^11 VP) combined with 60-min heating at 42℃. RESULTS: Two patients were cured with complete regressions of both injected and non-injected tumors and have survived for a long period up to date. Three patients responded to the novel therapy variously and eventually died from the disease, who survived 29, 15 and 13 months, respectively. CONCLUSION: The abscopal antitumor effect could be induced by the combination of H101 local intratumoral injection with heating.
出处 《癌症》 SCIE CAS CSCD 北大核心 2006年第8期919-924,共6页 Chinese Journal of Cancer
基金 国家"863计划"资助项目(No.2004AA2Z3A00)~~
关键词 肿瘤 生物治疗 溶瘤腺病毒 热疗 远端效应 Cancer Biotherapy Oncolytic adenovirus Heating Abscopal effect
  • 相关文献

参考文献6

二级参考文献27

  • 1[1]Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science,1996,274(5286):373- 376.
  • 2[2]Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer[J]. J Clin Oncol, 2001,19(2):289- 298.
  • 3[3]Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med,2000,6(8):879- 885.
  • 4[4]Ganly I, Eckhardt SG, Rodriguez GI, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer[J]. Clin Cancer Res,2000,6(3):798- 806.
  • 5[5]Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors[J]. Hum Gene Ther,2001,12(3): 219- 226.
  • 6[6]Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial[J]. Gene Ther, 2001, 8(4): 308- 315.
  • 7[7]Heise C,Wukkuans AM,Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy[J]. Cancer Res, 1999, 59: 2623- 2628.
  • 8[8]Heise C,Ganly I,Kim YT,et al.Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status[J]. Gene Ther, 2000,7:1925- 1929.
  • 9[9]Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents[J]. Nat Med,1997,3(6):639- 645.
  • 10[10]Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy[J]. Cancer Res, 2000,60(5):1193- 1196.

共引文献64

同被引文献92

引证文献12

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部